Kingston Health Sciences Centre Research Institute (KHSC-RI) has launched the first-ever Health Canada-approved clinical trial studying at-home micro-dose use of psilocybin to treat Generalized Anxiety Disorder (GAD).
The Phase 2a study will recruit 60 adults with GAD to test whether daily, non-hallucinogenic doses of psilocybin can safely and effectively ease anxiety symptoms. Participants will take the treatment at home for four weeks, followed by an extension or placebo.
“This represents a major shift — a new way of targeting anxiety without sedation or emotional numbing,” said Dr. Claudio Soares, principal investigator at KHSC-RI.
GAD affects more than 1.6 million Canadians, and many patients face limited treatment options.
Supported by Southeastern Ontario Academic Medical Organization and Diamond Therapeutics, the trial marks a milestone in mental health research.
People living with GAD who want to learn more or participate can contact the research team by email.
Story by Alyssa Brush
What’s open and closed in Kingston this Thanksgiving Monday
Sweet fall fun: Fallin’ for Maple festival brings family magic to Tamworth
Gaels women's hockey team excited ahead of season opener
Mail to move again: Postal workers to begin rotating strikes
L&A County paramedics honoured with national medals for decades of service
